WSW, NY, July 31st, 2026, FinanceWire
PolyPid (Nasdaq: PYPD) announced on July 29 that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for D-PLEX₁₀₀, its lead product candidate for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery. What stands out here, beyond the obvious good news, is that the FDA granted the application Priority Review, setting a target action date of November 28, 2026, approximately one quarter ahead of the company’s previously communicated first quarter 2027 guidance.
Priority Review is not a small feat. It shortens the FDA’s target review timeline from ten months to approximately six months, a designation granted to applications for drugs that may provide significant improvements in the treatment, diagnosis, or prevention of serious conditions.
The Azurity Partnership, and the Impressive Economics Hiding in Plain Sight
The NDA acceptance arrives just eight days after PolyPid announced an exclusive commercialization partnership with Azurity Pharmaceuticals for D-PLEX₁₀₀ in the U.S. and Canada. Under that deal, PolyPid received $15 million upfront at signing and is now owed a second $15 million milestone triggered by the NDA acceptance, completing $30 million in upfront and near-term milestone payments. The company is eligible for up to approximately $290 million in additional regulatory, development, and sales-based milestones.
However, potentially even more important, is the fact that the deal includes significant tiered royalties ranging from mid-teen to mid-twenties percentages above and beyond the milestone payments. Surgical site infections are estimated to be costing up to $10 billion a year in the United States. The long term sales potential here is hard to overstate, and thus, so are the royalties PolyPid could receive. In parallel, PolyPid will manufacture and supply D-PLEX₁₀₀ to Azurity at a transfer price, providing additional potential revenue. So while $320 million may have been the headline, it actually may turn out to be just a small part of its total value for PolyPid. So, between the royalty and the transfer price, PolyPid seems to be well positioned to potentially capture a significant portion of the end sale of the product.
A notable parallel arm of the deal, that was buried in the news, is that the companies are planning to work together to potentially pursue label expansion, and Azurity will be funding those clinical programs, significantly minimizing the costs to PolyPid, while potentially expanding the long term sales of the drug and thus, the major royalties PolyPid could be positioned to receive.
PolyPid structured the deal to retain full ownership of its Kynatrix platform, its broader pipeline, global commercial rights outside the U.S. and Canada, and manufacturing rights worldwide. The partnership monetizes D-PLEX₁₀₀ in its largest market by a partner that is experienced in taking specialty therapeutics to market, while keeping the underlying technology, which PolyPid is already developing additional applications for (such as its metabolic program), in the company’s hands.
Backed by Outstanding Phase 3 Data
The NDA is supported by data from the company’s pivotal Phase 3 trial, which enrolled 798 patients undergoing large-incision abdominal colorectal surgery. D-PLEX₁₀₀ achieved its primary composite endpoint with a 40% reduction (10.9% vs. 18.1%, p=0.0039) and demonstrated a 60% relative risk reduction at the key secondary endpoint measuring surgical site infection incidence (3.8% vs. 9.5%, p=0.0013). A third key secondary showed a 62% reduction in patients with clinically significant wound complications (p=0.0103). D-PLEX₁₀₀ holds Breakthrough Therapy, Fast Track, and Qualified Infectious Disease Product designations from the FDA, the last of which adds five years of market exclusivity upon approval.
A Different Approach
Surgical site infections remain among the most common hospital-acquired complications following abdominal surgery, and standard antibiotic prevention has well-documented limitations, particularly against drug-resistant bacteria. D-PLEX₁₀₀ takes a different approach: a paste applied directly into the surgical wound at closure, built on PolyPid’s proprietary Kynatrix technology, which releases the broad-spectrum antibiotic doxycycline locally over approximately 30 days.
With the NDA accepted ahead of the company’s own timeline, attention turns to the remaining catalysts ahead of the November 28 PDUFA target date. The FDA’s on-site manufacturing inspection of PolyPid’s sterile production facility in Israel is expected in the coming months; the company completed a successful GMP inspection by the Israeli Ministry of Health under the EU-Israel framework in September 2025. What’s notable is that the NDA acceptance letter, according to the company’s announcement, identified no filing review issues. Management has targeted a U.S. commercial launch in early 2027 with Azurity leading the rollout. PolyPid is also preparing a Marketing Authorization Application submission in Europe.
PolyPid originally guided for a first quarter 2027 FDA decision. Instead, the NDA was accepted with Priority Review and no filing review issues, pulling the target date to November 28, 2026. While risks still remain, and the FDA still needs to approve the drug, PolyPid seems to be uniquely positioned, with $30 million in near-term payments secured, a strong commercial partner already executing launch preparations, and full ownership of the Kynatrix platform intact. PolyPid now enters the FDA review period ahead of schedule and with a strengthened balance sheet, all while the market may not have yet fully digested the potential of their technology platform, and the total economic potential of their recent partnership deal.
>> This report was originally published on Wall Street Sync. Click here to view the original.
Recent News Highlights from PolyPid (NASDAQ: PYPD)
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. Wall Street Wire is not a broker-dealer or investment adviser. References to market size estimates, valuations, price targets, or other third-party data are provided strictly for informational purposes. Wall Street Wire receives cash compensation from PolyPid Ltd. (the “Issuer”) for coverage and awareness services, which are provided on an ongoing subscription basis. The content above is a form of paid advertising and promotion and is for informational purposes only and does not constitute financial or investment advice. This article may contain forward-looking statements about the Issuer’s products, plans, or prospects that are subject to risks and uncertainties; actual results may differ materially, and readers should review the Issuer’s public filings on SEC EDGAR (sec.gov/edgar) for full risk factors. Market size figures, research estimates, or other third-party data referenced in this article are quoted from publicly available sources believed to be reliable; however, we do not independently verify or endorse them, and additional figures or estimates may exist. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. This article should not be considered an official communication of the Issuer.